Coverage Alpha reads pharmaceutical earnings the way the market actually gets made — through pricing, coverage, and contracting. A two-page research brief, within 48 hours of the call.
Join the founding list Read a sample issueEquity research treats access as a footnote. Formulary databases are backward-looking with no narrative. Consultants connect the dots quarterly, at $50,000, for one client at a time. Nobody publishes the seam.
Interim issues cover the events that move access between earnings: January and July formulary template drops, WAC actions, and Part D policy changes.
Competitor posture, contracting leverage, and rebate implications — synthesized before your next bid cycle discussion.
Asset-level read-through, buyer-appetite signals, and the access assumptions your diligence models should be using.
The access variable equity research can't model — as a differentiated input to theses and client work.
Every issue is free through the end of 2026. Paid subscriptions open in January 2027 at $199 per month. Anyone on the list before then is a founding subscriber and locks $39 per month for the life of the subscription.
Every issue free through the end of the year. The first 100 subscribers lock the founding rate of $39 per month against the $59 list price — for the life of the subscription.
Independent publication. Not investment advice. Unsubscribe anytime.